Vyriad
PrivateLast Round
Series B
Dec 23, 2025
Total Funding Raised
$150.38M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vyriad operates in Healthcare & Life Sciences and is based in Rochester, Minnesota. Its latest recorded funding round was a Series B round in December 2025.
Vyriad is a biotechnology company that develops targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins for oncolytic virotherapy, in vivo gene therapy, and gene editing applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vyriad Comparables
Compare Vyriad with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ensoma | 82% | |
| AbbVie | 81% | |
| Eli Lilly and Company | 81% |
For institutional investors. Book with your work email.
Vyriad Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 23, 2025 | ||||
| Series B | May 17, 2022 | ||||
| Grant | Dec 1, 2020 | ||||
| Strategic | Nov 6, 2019 | ||||
| Grant | Apr 13, 2018 | ||||
Debt | Mar 28, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vyriad Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Mirae Asset | Series B |
| NIH RADx | Grant |
| Mayo Clinic Ventures | Series B |
| Rochester Area Economic Development, Inc. | Debt, Grant, Series B |
| Southeast Minnesota Capital Partners | Grant, Series B |
| Mirae Asset Venture Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 23, 2025
$25M round led by Harry H. Stine and Stine Seed Company.
- Dec 16, 2025
Presented at the ASH 2025 conference.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 14, 2026
Vyriad and Mayo Clinic are developing VV169, an in vivo CAR-T treatment designed to create CAR-T cells inside the body, as they recruit up to 40 patients with multiple myeloma for a Phase 1 clinical trial in Minnesota on Sep 14th '26.
For institutional investors. Book with your work email.
Vyriad Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vyriad's valuation, stock price, and market status.
Is Vyriad a public or private company?
Vyriad is a private company.
What is the current stock price of Vyriad?
Vyriad is a private company, so its shares have no public market price. Caplight tracks Vyriad's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vyriad worth (valuation)?
Valuation information for Vyriad is not publicly available.
Can I buy Vyriad stock?
Vyriad shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vyriad's last funding round?
Vyriad's most recent funding round was Series B on December 23, 2025.
Who are the main investors in Vyriad?
Key investors in Vyriad include National Cancer Institute, Mirae Asset, NIH RADx, Mayo Clinic Ventures, Rochester Area Economic Development, Inc..
Will Vyriad IPO soon?
No public IPO plans have been announced for Vyriad.
How can I track Vyriad secondary market activity?
Caplight tracks bids, offers, and trades in Vyriad's shares on secondary markets.